UMIN ID: UMIN000001014
Registered date:04/02/2008
Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinoma
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Advanced esophageal cancer refractory to standard therapeutic modality |
| Date of first enrollment | 2008/02/01 |
| Target sample size | 6 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Peptide vaccine therapy |
Outcome(s)
| Primary Outcome | Safety |
|---|---|
| Secondary Outcome | Antitumor immune responses |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Pregnancy Uncontrolled infection Uncontrolled brain metastasis |
Related Information
| Primary Sponsor | University of Tokyo |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Government |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | Japan |
| Telephone | |
| Affiliation | Institute of Medical Science, University of Tokyo Surgery and Bioengeering |
| scientific contact | |
| Name | Masahisa Jinushi |
| Address | 4-6-1, Shirokane-dai, Minato-ku Japan |
| Telephone | 03-5449-5582 |
| Affiliation | Institute of Medical Science, University of Tokyo Surgery and Bioengeering |